CSL Behring
🇧🇪Belgium
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Phase 4
Completed
- Conditions
- Common Variable ImmunodeficiencyAgammaglobulinemia
- Interventions
- Drug: Vivaglobin
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 18
- Registration Number
- NCT00520494
- Locations
- 🇪🇸
Contact CSL Behring for facility details, Madrid, Spain
Human Fibrinogen - Pharmacokinetics
Phase 2
Completed
- Conditions
- Fibrinogen Deficiency
- Interventions
- Biological: Human Fibrinogen Concentrate
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 15
- Registration Number
- NCT00496262
- Locations
- 🇮🇹
Contact CSL Behring for facility details, Vicenza, Italy
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
Phase 3
Completed
- Conditions
- Primary Immune Deficiency
- Interventions
- Biological: Human Normal Immunoglobulin for Subcutaneous Administration
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 49
- Registration Number
- NCT00419341
- Locations
- 🇺🇸
Study Site, Dallas, Texas, United States
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Phase 3
Completed
- Conditions
- AgammaglobulinemiaCommon Variable ImmunodeficiencyIgG Deficiency
- Interventions
- Drug: Immunoglobulins Intravenous (Human)
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 55
- Registration Number
- NCT00322556
- Locations
- 🇺🇸
Contact CSL Behring for facility details, Dallas, Texas, United States
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
Phase 3
Completed
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: C1 Esterase Inhibitor
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 57
- Registration Number
- NCT00292981
- Locations
- 🇨🇦
Contact CSL Behring for facility details, Ottawa, Ontario, Canada
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
Phase 4
Completed
- Conditions
- EmphysemaAlpha1-proteinase Inhibitor Deficiency
- Interventions
- Biological: Alpha1-proteinase inhibitorOther: Placebo
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 180
- Registration Number
- NCT00261833
- Locations
- 🇸🇪
Study Site, Malmo, Sweden
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
Phase 4
Completed
- Conditions
- Blood Coagulation DisordersBlood Platelet DisordersHematologic DiseaseVon Willebrand Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 30
- Registration Number
- NCT00168090
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
Phase 3
Completed
- Conditions
- IgG DeficiencyCommon Variable ImmunodeficiencyAgammaglobulinemia
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 42
- Registration Number
- NCT00168012
Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Phase 3
Completed
- Conditions
- AgammaglobulinemiaIgG DeficiencyCommon Variable Immunodeficiency
- Interventions
- Drug: Immunoglobulins Intravenous (Human)
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 89
- Registration Number
- NCT00168025
Prothrombin Complex Concentrate for Anticoagulant Reversal
Phase 3
Completed
- Conditions
- Acquired Coagulation Factor Deficiency
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 40
- Registration Number
- NCT00168077
- Locations
- 🇨🇭
Clinical Trials Registration Coordinator, Zuerich, Switzerland
🇩🇪For information on sites in Europe, please contact our clinical research team in, Marburg, Germany
© Copyright 2025. All Rights Reserved by MedPath